The role of immunotherapy in prevention of preeclampsia and influence on the condition of pregnant women and newborns

Despite on modern success in the prevention, diagnosis, and treatment of hypertensive disorders (HD) in pregnancy, the preeclampsia (PE) affects around 2 to 5% of pregnancies, and has no tendency to decrease, and perinatal mortality is from 18 to 30%. The aim of the provided study was to investigate the condition of the pregnant women and newborns born from mothers with various HD depending on the method of prevention of this pathology. It was analyzed the condition of 130 pregnant women and newborns from mothers at risk for PE, which received various methods of PE prevention during pregnancy. In groups studied pregnancy outcomes, frequency, and the structure of HD, methods of delivery, the incidence of morbidity, and mortality of newborns depending on the method of preventive therapy of HD. The Pearson criterion χ² was used to assess the relation between quality signs. During of the study it was established that traditional preventive treatment reduces the development of hypertensive disorders almost by 2 times (p <0.05), the preventive therapy with immunotherapy developed by us proved to be effective by 4 times (p <0.01) in compare with pregnant women who did not receive preventive treatment. The prevention of HD during pregnancy with using immunotherapy allowed preventing severe forms of pathology and complications, such as intrauterine growth restriction and antenatal fetal death, significantly reduced frequency of premature and operative births, indicators of perinatal mortality and general morbidity of newborns.